EMP2 and breast carcinoma: Worthy, the signature demonstrated to predict poor outcomes in breast cancer patients exhibiting high transcriptional levels of ITGA11, THBS1, FN1, EMP1, ITGA2, FYN, SPP1, and EMP2.